Bio-Rad Launches Recombinant Luteinizing Hormone, Expanding its Critical Raw Materials Portfolio


Product Press Release

HERCULES, Calif – August 2, 2017 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announces the launch of recombinant Luteinizing Hormone (LH), which expands the company’s Critical Raw Material offerings. The recombinant Luteinizing Hormone is part of the pituitary hormone product line engineered for a wide range of diagnostic uses.

"Bio-Rad is committed to developing recombinant products and fulfilling our customers' needs," said Conrad Maurais, Bio-Rad Product Manager, Quality Systems Division. “This protein bolsters our line of pituitary hormones as a replacement for difficult-to-source human proteins and provides the added value of a reliable and consistent source.”

About Recombinant Luteinizing Hormone

Luteinizing Hormone (also known as lutropin and lutrophin) is primarily used to treat infertility, but it is also beneficial in the diagnosis of pituitary disorders and dysfunctions with the ovaries and testicles. The hormone is suitable as an integral component used in controls and/or calibrators of fertility monitoring, pituitary disorders, menopause, and other diagnostic assessments.

With over 25 years of experience providing critical raw materials, Bio-Rad is a leading provider of tumor marker antigens, and diagnostic proteins. For more information, please call 207-615-0571, email, or visit

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 8,350 people worldwide and had revenues exceeding $2 billion in 2016. For more information, please visit

Bio-Rad Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding plans to introduce new products and the opportunities that may result from such new products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “offers,” or similar expressions or the negative of those terms or expressions, although not all
forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.


Press contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications